LMNA抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using LMNA mouse mAb against Raw264.7 (1), PC-12 (2), THP-1 (3), A431 (4), MCF-7 (5) and Jurkat (6) cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human striated muscle tissues using LMNA mouse mAb with DAB staining.    

  
  

The LMNA antibody is a crucial tool in studying lamin A/C, proteins encoded by the LMNA gene, which play structural and regulatory roles in the nucleus. These proteins form part of the nuclear lamina, providing mechanical stability to the nuclear envelope and regulating chromatin organization, gene expression, and cellular signaling. Mutations in LMNA are linked to diverse disorders termed laminopathies, including muscular dystrophies, cardiomyopathy, progeria, and lipodystrophy. Antibodies targeting lamin A/C are widely used in research and diagnostics to investigate disease mechanisms, assess protein expression/localization, and validate LMNA mutations.

In research, LMNA antibodies help explore cellular aging, DNA repair, and stem cell differentiation. Clinically, they aid in diagnosing laminopathies via immunohistochemistry or Western blotting, detecting abnormal protein patterns in patient tissues. However, LMNA antibody specificity can vary due to splice variants (e.g., lamin A vs. lamin C) and post-translational modifications, necessitating careful validation. Commercial antibodies are often validated in knockout models to ensure reliability. Recent studies also highlight lamin A/C's role in cancer progression and metabolic diseases, expanding the antibody's applications. Challenges remain in standardizing detection protocols across tissues and addressing cross-reactivity with other intermediate filaments.